Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Oral hypoglycemic agents and insulin analogues Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Oral hypoglycemic agents and insulin analogues Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Insulin Secretagogues
      • 1.3.3 Alpha-glucosidase Inhibitors
      • 1.3.4 Insulin Sensitizers
    • 1.4 Market Segment by Application
      • 1.4.1 Global Oral hypoglycemic agents and insulin analogues Market Share by Application (2019-2025)
      • 1.4.2 Hospitals
      • 1.4.3 Drug Store
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Oral hypoglycemic agents and insulin analogues Market Size
      • 2.1.1 Global Oral hypoglycemic agents and insulin analogues Revenue 2014-2025
      • 2.1.2 Global Oral hypoglycemic agents and insulin analogues Sales 2014-2025
    • 2.2 Oral hypoglycemic agents and insulin analogues Growth Rate by Regions
      • 2.2.1 Global Oral hypoglycemic agents and insulin analogues Sales by Regions 2014-2019
      • 2.2.2 Global Oral hypoglycemic agents and insulin analogues Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Oral hypoglycemic agents and insulin analogues Sales by Manufacturers
      • 3.1.1 Oral hypoglycemic agents and insulin analogues Sales by Manufacturers 2014-2019
      • 3.1.2 Oral hypoglycemic agents and insulin analogues Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Oral hypoglycemic agents and insulin analogues Revenue by Manufacturers (2014-2019)
      • 3.2.2 Oral hypoglycemic agents and insulin analogues Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Oral hypoglycemic agents and insulin analogues Market Concentration Ratio (CR5 and HHI)
    • 3.3 Oral hypoglycemic agents and insulin analogues Price by Manufacturers
    • 3.4 Key Manufacturers Oral hypoglycemic agents and insulin analogues Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Oral hypoglycemic agents and insulin analogues Market
    • 3.6 Key Manufacturers Oral hypoglycemic agents and insulin analogues Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Insulin Secretagogues Sales and Revenue (2014-2019)
      • 4.1.2 Alpha-glucosidase Inhibitors Sales and Revenue (2014-2019)
      • 4.1.3 Insulin Sensitizers Sales and Revenue (2014-2019)
    • 4.2 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Type
    • 4.3 Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Type
    • 4.4 Oral hypoglycemic agents and insulin analogues Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Oral hypoglycemic agents and insulin analogues Sales by Application

    6 United States

    • 6.1 United States Oral hypoglycemic agents and insulin analogues Breakdown Data by Company
    • 6.2 United States Oral hypoglycemic agents and insulin analogues Breakdown Data by Type
    • 6.3 United States Oral hypoglycemic agents and insulin analogues Breakdown Data by Application

    7 European Union

    • 7.1 European Union Oral hypoglycemic agents and insulin analogues Breakdown Data by Company
    • 7.2 European Union Oral hypoglycemic agents and insulin analogues Breakdown Data by Type
    • 7.3 European Union Oral hypoglycemic agents and insulin analogues Breakdown Data by Application

    8 China

    • 8.1 China Oral hypoglycemic agents and insulin analogues Breakdown Data by Company
    • 8.2 China Oral hypoglycemic agents and insulin analogues Breakdown Data by Type
    • 8.3 China Oral hypoglycemic agents and insulin analogues Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Oral hypoglycemic agents and insulin analogues Breakdown Data by Company
    • 9.2 Rest of World Oral hypoglycemic agents and insulin analogues Breakdown Data by Type
    • 9.3 Rest of World Oral hypoglycemic agents and insulin analogues Breakdown Data by Application
    • 9.4 Rest of World Oral hypoglycemic agents and insulin analogues Breakdown Data by Countries
      • 9.4.1 Rest of World Oral hypoglycemic agents and insulin analogues Sales by Countries
      • 9.4.2 Rest of World Oral hypoglycemic agents and insulin analogues Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Sanofi-Aventis
      • 10.1.1 Sanofi-Aventis Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Oral hypoglycemic agents and insulin analogues
      • 10.1.4 Oral hypoglycemic agents and insulin analogues Product Introduction
      • 10.1.5 Sanofi-Aventis Recent Development
    • 10.2 Ganlee
      • 10.2.1 Ganlee Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Oral hypoglycemic agents and insulin analogues
      • 10.2.4 Oral hypoglycemic agents and insulin analogues Product Introduction
      • 10.2.5 Ganlee Recent Development
    • 10.3 Biocon
      • 10.3.1 Biocon Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Oral hypoglycemic agents and insulin analogues
      • 10.3.4 Oral hypoglycemic agents and insulin analogues Product Introduction
      • 10.3.5 Biocon Recent Development
    • 10.4 Novo Nordisk
      • 10.4.1 Novo Nordisk Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Oral hypoglycemic agents and insulin analogues
      • 10.4.4 Oral hypoglycemic agents and insulin analogues Product Introduction
      • 10.4.5 Novo Nordisk Recent Development
    • 10.5 Eli Lilly
      • 10.5.1 Eli Lilly Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Oral hypoglycemic agents and insulin analogues
      • 10.5.4 Oral hypoglycemic agents and insulin analogues Product Introduction
      • 10.5.5 Eli Lilly Recent Development
    • 10.6 Tonghua Dongbao
      • 10.6.1 Tonghua Dongbao Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Oral hypoglycemic agents and insulin analogues
      • 10.6.4 Oral hypoglycemic agents and insulin analogues Product Introduction
      • 10.6.5 Tonghua Dongbao Recent Development
    • 10.7 United Laboratory
      • 10.7.1 United Laboratory Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Oral hypoglycemic agents and insulin analogues
      • 10.7.4 Oral hypoglycemic agents and insulin analogues Product Introduction
      • 10.7.5 United Laboratory Recent Development
    • 10.8 Jiangsu Wanbang
      • 10.8.1 Jiangsu Wanbang Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Oral hypoglycemic agents and insulin analogues
      • 10.8.4 Oral hypoglycemic agents and insulin analogues Product Introduction
      • 10.8.5 Jiangsu Wanbang Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Oral hypoglycemic agents and insulin analogues Sales Channels
      • 11.2.2 Oral hypoglycemic agents and insulin analogues Distributors
    • 11.3 Oral hypoglycemic agents and insulin analogues Customers

    12 Market Forecast

    • 12.1 Global Oral hypoglycemic agents and insulin analogues Sales and Revenue Forecast 2019-2025
    • 12.2 Global Oral hypoglycemic agents and insulin analogues Sales Forecast by Type
    • 12.3 Global Oral hypoglycemic agents and insulin analogues Sales Forecast by Application
    • 12.4 Oral hypoglycemic agents and insulin analogues Forecast by Regions
      • 12.4.1 Global Oral hypoglycemic agents and insulin analogues Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Oral hypoglycemic agents and insulin analogues Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Oral hypoglycemic agents and insulin analogues is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Oral hypoglycemic agents and insulin analogues.

      This report studies the global market size of Oral hypoglycemic agents and insulin analogues, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Oral hypoglycemic agents and insulin analogues sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Sanofi-Aventis
      Ganlee
      Biocon
      Novo Nordisk
      Eli Lilly
      Tonghua Dongbao
      United Laboratory
      Jiangsu Wanbang

      Market Segment by Product Type
      Insulin Secretagogues
      Alpha-glucosidase Inhibitors
      Insulin Sensitizers

      Market Segment by Application
      Hospitals
      Drug Store
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Oral hypoglycemic agents and insulin analogues status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Oral hypoglycemic agents and insulin analogues manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Oral hypoglycemic agents and insulin analogues are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now